Lexaria Bioscience earnings were -$7.7M for the trailing 12 months ending May 31, 2026, with N/A growth year over year. The latest LEXX earnings report on May 31, 2026 announced Q2 2026 earnings of -$2.0M, up 37.3% from last quarter. For the last reported fiscal year 2025 ending Aug 31, 2025, LEXX reported annual earnings of -$11.9M, with 105.4% growth. The next LEXX earnings date is Nov 25, 2026.
What were Lexaria Bioscience's earnings last quarter?
On LEXX's earnings call on Jul 13, 2026, Lexaria Bioscience (NASDAQ: LEXX) reported Q2 2026 earnings per share (EPS) of -$1.20, up 61.9% year over year. Total LEXX earnings for the quarter were -$1.99 million. In the same quarter last year, Lexaria Bioscience's earnings per share (EPS) was -$3.15.
The next LEXX earnings call is Nov 25, 2026. Add LEXX to your watchlist to be reminded of Lexaria Bioscience's next earnings date.
Is Lexaria Bioscience profitable or losing money?
As of the last Lexaria Bioscience earnings report, Lexaria Bioscience is currently losing money. Lexaria Bioscience's net profit (also called net income) for the twelve months ending May 31, 2026 was -$7.73 million, a 32.12% decrease year over year.
What was LEXX's earnings growth in the past year?
As of Lexaria Bioscience's earnings date in Jul 13, 2026, Lexaria Bioscience's earnings has grown year over year. LEXX earnings in the past year totalled -$7.73 million.
What are Lexaria Bioscience's earnings expectations?
The current EPS estimate for Lexaria Bioscience's earnings report in Nov 25, 2026 is -$0.90.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.